JUBLINGREA Jubilant Ingrevia Q2 FY26 results (Jul–Sep 2025) and concall
Jubilant Ingrevia reported a strong Q2 FY26 with 7% YoY revenue growth and 18% YoY PAT increase, driven by robust volume expansion and strong performance in Specialty Chemicals. The company achieved its highest quarterly revenue in 10 quarters and made significant progress in its CDMO pipeline and sustainability initiatives. However, pricing pressures in the Nutrition and Chemical Intermediates segments, along with short-term market volatility, impacted margins in those areas.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| Revenue | 1,057 | 1,051 | 1,038 | 1,121 |
| EBITDA | 138 | 147 | 142 | 135 |
| Net profit | 69 | 74 | 75 | 69 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
